Trial Search Results
Biologically Focused Therapy of Treatment-Refractory MDS Patients
This non interventional study examines the feasibility of using patient specific therapeutic screening method, ex vivo to enhance current treatment recommendations in a clinically feasible time frame of 30 days.
Stanford is currently not accepting patients for this trial.
Collaborator: Notable Labs Inc.
- Provide informed consent;
- Myelodysplastic syndrome as defined by WHO classification (see Appendix 2), or MDS/MPN
with >= 5% blasts in the bone marrow or peripheral blood, including chronic
myelomonocytic leukemia (CMML) 1 and 2 by WHO classification
- Relapsed/refractory disease, defined as failed or are ineligible for hypomethylating
- Cytogenetics reported
- Hypoplastic MDS
- Patients without adequate marrow samples for ex vivo analysis
Ages Eligible for Study
18 Years - N/A
Genders Eligible for Study